RxDoctor Payments Data

Steven Dresner, MD

Urology · Columbia, MONPI 1598745481

Payments from drug & device makers

$7,047in general payments, 2019–2025

Across 171 payments — averaging $41.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avyxa Pharma, LLC$4K
  • Johnson & Johnson$627
  • Astellas Pharma US Inc$307
  • Convatec Inc.$268
  • Agiliti Health, Inc.$258
  • Pfizer$254
  • plus $2K from 28 others

What the payments were for

  • Speaking & faculty fees$2,00028%
  • Travel & lodging$1,34319%
  • Food & beverage$3,67852%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,047 in reported general payments places this provider in the 65th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$408,955
Medicare patients
760
Services billed
9,852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide31$428,863
Abiraterone Acetate21$15,416
GemtesaVibegron16$12,515
Tamsulosin Hcl670$9,516
Finasteride391$5,467
Oxybutynin Chloride ErOxybutynin Chloride97$2,977
Potassium Citrate ErPotassium Citrate11$2,100
Dutasteride32$692
Potassium Chloride18$577
Bicalutamide25$411
Alfuzosin Hcl ErAlfuzosin Hcl15$395
Prednisone41$348
Doxazosin Mesylate23$336
Levofloxacin119$250
Cefdinir82$248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$307$428,86331 claims
Sumitomo Pharma America, Inc.Gemtesa$48$12,51516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 250 urology providers in Missouri.

Other urology in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →